Our firm is about people. That is our motto and that will always be our reality.
We do our best to get to know our clients, understand their situations, and get them the compensation they deserve.
At TorHoerman Law, we believe that if we continue to focus on the people that we represent, and continue to be true to the people that we are – justice will always be served.
Without our team, we would’nt be able to provide our clients with anything close to the level of service they receive when they work with us.
The TorHoerman Law Team commits to the sincere belief that those injured by the misconduct of others, especially large corporate profit mongers, deserve justice for their injuries.
Our team is what has made TorHoerman Law a very special place since 2009.
The Bard Atherectomy Catheter Lawsuit investigation centers on reports of device malfunctions during medical procedures, including serious injuries and deaths linked to fractured components and failed plaque removal.
TorHoerman Law is investigating potential legal claims related to injuries and deaths linked to the Bard Atherectomy Catheter system.
On this page, we’ll discuss the Bard Atherectomy Catheter Lawsuit investigation, the recent recall of the Rotarex Atherectomy System due to serious safety concerns, how and why these devices are used, and much more.
The Bard Atherectomy Catheter Lawsuit investigation centers on a high-risk medical device now under scrutiny for causing serious harm to patients.
The Rotarex Atherectomy Catheter, manufactured by Bard Peripheral Vascular, is used by medical professionals to remove plaque and blood clots from arteries during minimally invasive procedures.
However, the device has been linked to multiple injuries and at least four deaths due to critical design failures.
Reports indicate that the catheter’s internal rotating helix can fracture during use, leading to vessel damage, severe bleeding, and in some cases, death.
In February 2025, the US Food and Drug Administration (FDA) issued a Class I recall—the most serious recall category—after dozens of incidents involving injuries and emergency interventions were reported.
Bard advised physicians to follow revised safety guidelines, including the use of reinforced sheaths and techniques to maintain adequate blood flow during procedures.
Despite these measures, the risks associated with the device have raised significant legal and medical concerns.
Patients and families affected by the Bard Atherectomy Catheter may be eligible to file lawsuits for the harm caused.
If you or a loved one suffered severe bleeding, vessel damage, or other complications during a procedure involving the Bard Atherectomy Catheter, you may be eligible to pursue compensation.
Contact us for a free consultation.
The Bard Atherectomy Catheter lawsuit investigation focuses on a dangerous pattern of device failures tied to serious vascular injuries and patient deaths.
The Rotarex Atherectomy Catheter is a mechanical thrombectomy device used by physicians to remove occlusions from native peripheral arteries or artificial bypasses, typically in the lower limbs.
It is intended for use in carefully controlled, image-guided settings, where the rotating catheter shaft helps dislodge and extract arterial blockages.
However, reports submitted to the FDA revealed that the catheter shaft and inner helix component can fracture or break during use—often inside fragile blood vessels.
These failures have led to severe complications, including embolization, severe bleeding, emergency surgery, and at least four patient deaths.

In many cases, broken fragments had to be surgically retrieved from within the artery, presenting extreme danger and delay in treatment.
The investigation is examining whether Bard failed to adequately warn healthcare providers of these risks or correct known safety issues in time.
If you or a loved one experienced severe complications such as internal bleeding, vessel damage, or required emergency surgery after a procedure involving the Bard Atherectomy Catheter, you may be eligible to pursue compensation.
Contact us for a free consultation.
Bard Peripheral Vascular, a subsidiary of Becton, Dickinson and Company, issued a recall of several Rotarex Atherectomy Systems due to an urgent atherectomy catheter system issue.
The recall was prompted by serious safety concerns involving the structural integrity of the catheter’s rotating inner component—known as the helix portion.
The FDA classified the action as a Class I recall, the most critical level, due to the risk of life-threatening injuries or death.
The primary failure mode involves helix fracture, where the rotating part of the device breaks during use, potentially resulting in damage to the arterial wall, internal bleeding, or embolic events.
The recalled devices are used to remove occlusive material in native peripheral arteries and bypass grafts.
According to post-market surveillance and adverse event reports, fractures may occur when the device is not kept in constant catheter movement, or when used in tortuous vessels such as near a vessel bifurcation.
Improper technique or anatomical challenges can also contribute to catheter overheating, which further increases the likelihood of structural failure.
Bard’s recall included a Medical Device Correction Letter that outlined revised safety instructions aimed at reducing procedural risks and improving medical device safety.

The correction letter emphasized key handling precautions, such as:
Despite these changes, serious injuries—including vascular damage and deaths—have continued to surface, raising questions about the device’s design, risk communication, and continued use in peripheral artery interventions.
Complications linked to the Bard Atherectomy Catheter appear to stem from structural failures within the device during use in delicate arterial environments.
The catheter’s rotating helix, designed to remove arterial plaque and thrombus, can fracture or break off inside the vessel.
This may occur when the device is subjected to stress, particularly if used without a suitably reinforced sheath or in sharply curved vessels.
When fragments break free, they can damage vessel walls, cause downstream blockages, or lead to uncontrolled internal bleeding.
In some cases, broken components must be surgically removed, prolonging procedure time and increasing the risk of further injury.
These dangerous outcomes have been reported in both routine and emergency vascular procedures.

Common complications linked to the Bard Atherectomy Catheter include:
Many of the injuries linked to the Bard Rotarex Atherectomy Catheter may have been preventable with earlier intervention, clearer warnings, and design modifications.
Reports submitted to the FDA suggest that a significant number of complications—such as vessel injury, internal bleeding, and the need for emergency surgery—were caused by a broken catheter during use.
These breakages often occurred due to stress on the device during catheter advancement, especially in complex or curved arterial pathways.
While Bard eventually issued a recall and updated usage guidelines, questions remain about whether the company acted quickly enough to protect patients.
Several catheter advancement related factors and certain procedural factors appear to have contributed to device failure.
For example, advancing the catheter through a vessel with sharp bends or narrowing may increase pressure on the internal helix, heightening the risk of fracture.
Failure to maintain adequate blood flow or monitor for resistance during use also played a role in several adverse events.
Had these risks been more clearly communicated through timely medical device recalls or proactive physician education, some of the most serious injuries and deaths might have been avoided.
A lawsuit investigation will likely focus on whether Bard failed to implement safeguards or issue warnings when early signs of danger became apparent.
The legal investigation into the Bard Atherectomy Catheter comes at a time when Bard Peripheral Vascular is already facing significant scrutiny in other product liability cases.
The company, a subsidiary of Becton, Dickinson and Company (BD), is currently the target of ongoing Bard PowerPort lawsuits filed by patients nationwide.
These lawsuits allege that the defective Bard PowerPort device, an implantable port catheter used for long-term vascular access, can fracture, migrate, or cause infections, leading to serious complications.
Plaintiffs claim that Bard failed to properly test the device or warn healthcare providers about its risks—allegations that mirror growing concerns about Bard’s oversight of its other medical products.
Bard Peripheral Vascular, Inc. was formerly part of C.R. Bard, Inc., which was acquired by BD in 2017.
BD continued to operate Bard’s vascular and interventional product lines, including the PowerPort and the Rotarex Atherectomy System, under the Bard brand.
Now, both the Bard PowerPort litigation and the new investigation into the atherectomy catheter system raise questions about the company’s overall commitment to medical device safety.

In both cases, device failures have been linked to serious patient injuries and deaths.
As the catheter lawsuit investigation progresses, lawyers are likely to examine whether the company’s corporate response to known risks followed the same patterns seen in the PowerPort cases.
The emerging litigation may signal broader systemic issues within the company’s product design, testing, and post-market safety protocols.
You may qualify for a Rotarex Atherectomy System lawsuit if you or a loved one suffered serious complications during a procedure involving the device.
Common qualifying injuries include severe bleeding, vessel damage, emergency surgery, or death caused by a fractured or malfunctioning catheter.
The device’s rotating helix, which is intended to break up blockages in narrowed arteries, has been reported to fracture during use, releasing metal fragments inside the blood vessels.
These broken pieces can puncture arterial walls, block blood flow, or migrate to other areas of the body, causing extensive damage.
Lawsuits are being evaluated for individuals who underwent vascular procedures for peripheral artery disease (PAD) and experienced sudden complications related to the catheter.
Many of these procedures involved unnecessary or overly aggressive use of atherectomy systems, increasing the likelihood of harm.
Patients who required additional surgeries to retrieve device fragments or who suffered permanent vascular damage may be eligible to file a claim.

Claims may also be considered in cases of wrongful death following a failed procedure using the Rotarex system.
Legal investigations are examining whether Bard Peripheral Vascular failed to adequately warn physicians of the risks or provide sufficient safety guidance.
If your injury occurred during a procedure involving this device, you may have a valid case.
TorHoerman Law is actively investigating claims related to injuries and deaths caused by the Bard Rotarex Atherectomy Catheter.
Our legal team is reviewing cases involving device malfunctions that led to severe bleeding, vessel injury, emergency interventions, or loss of life.
We are committed to helping individuals and families understand their legal rights and pursue the compensation they may be owed.

If you or a loved one experienced complications during a procedure involving a Bard atherectomy catheter, you may be eligible to file a claim.
Our firm has extensive experience in defective medical device litigation and will handle your case with the compassion, focus, and determination it deserves.
The Bard Rotarex Atherectomy Catheter is primarily used to remove plaque or thrombus from peripheral arteries, particularly in the legs.
These procedures are commonly performed to treat peripheral artery disease (PAD), where narrowed or blocked vessels reduce blood flow to the limbs.
The device is intended for use in both native peripheral arteries and native or artificial bypasses, including vessels reconstructed through surgery or grafting.
It can also be used in patients with prior vascular implants or repairs, such as stent grafts or bypass surgeries.
However, these conditions may increase procedural risks, as previously repaired vessels can present uneven surfaces, narrowing, or scar tissue that complicate catheter advancement.
When navigating around or through these areas, there is a higher likelihood of mechanical stress on the device, which could contribute to malfunction or injury.
Patients whose peripheral arteries are fitted with stents, grafts, or previous surgical modifications may be at increased risk for catheter malfunction.
Additionally, those with calcified vessel segments—arteries hardened by mineral buildup—are more likely to experience device-related problems, as the catheter’s rotating components can snag or fracture under pressure.
Several procedural factors can contribute to catheter malfunction, including how the device is handled during insertion and operation.
One critical recommendation is to reduce catheter advancement when resistance is felt, as forcing the device through difficult anatomy can lead to stress fractures.
Physicians are advised to monitor the catheter closely, especially during use in vessels with sharp curves or narrowing, as these areas can increase localized pressure on the device.
Patients with certain anatomical characteristics—such as tortuous vessels or heavily calcified arteries—are at higher risk for complications.
Maintaining continuous blood flow and observing continuous drainage during the procedure are essential to verify that the catheter is functioning properly and not blocked.
When these signs are absent, the device may be overheating or failing internally.
Imaging techniques like digital subtraction angiography and proper contrast injection are used to guide the procedure and detect early signs of malfunction.
Failing to recognize these warning signs in real time has been identified as a contributing factor in multiple adverse events, including catheter breakage, vessel injury, and emergency interventions.
The Bard Rotarex Atherectomy Catheter relies on a rotating catheter head that houses a high-speed helix portion, which is designed to break up and remove plaque or thrombus from within arteries.
However, this internal helix can fracture under stress, especially when the device encounters resistance or is used in sharply curved vessels.
A fractured catheter shaft or one catheter head breaking off during use can lead to vessel damage, internal bleeding, or embolization.
Bending or kinking during procedures—especially in anatomically challenging areas—can weaken structural components, particularly if a kink resistant sheath is not used.
The device is controlled by a control unit, which may emit audible control unit alarms when abnormal function is detected, but failure to respond to these alarms may allow a malfunction to worsen.
Catheter bend is a known risk factor, as even minor flexion can cause fatigue in the rotating parts over time.
In some cases, thermal stress or lack of adequate blood flow may contribute to catheter overheating, further increasing the likelihood of helix fracture.
These design-related failures have been central to reports of injuries and deaths, prompting the current FDA recall and legal investigation.
When the Bard Rotarex Atherectomy Catheter fails—often due to helix fracture, catheter shaft breakage, or overheating—patients may suffer serious, potentially life-threatening complications.
These injuries typically occur during procedures to remove blockages in peripheral arteries, especially when the catheter is stressed by difficult anatomy or improper technique.
In many reported cases, broken catheter components have lodged in blood vessels or migrated, requiring emergency surgery to retrieve them.
Some patients have experienced long-term damage or death as a result of these malfunctions.
The most commonly reported complications include:
These outcomes have prompted a growing number of lawsuits and triggered a Class I recall by the FDA.
Owner & Attorney - TorHoerman Law
Here, at TorHoerman Law, we’re committed to helping victims get the justice they deserve.
Since 2009, we have successfully collected over $4 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TorHoerman Law, we believe that if we continue to focus on the people that we represent, and continue to be true to the people that we are – justice will always be served.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.
In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.
In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.
In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.
In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
Here, at TorHoerman Law, we’re committed to helping victims get the justice they deserve.
Since 2009, we have successfully collected over $4 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?